Duopharma Biotech Bhd
KLSE:DPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Duopharma Biotech Bhd
KLSE:DPHARMA
|
MY |
|
Danaher Corp
NYSE:DHR
|
US |
|
TomTom NV
OTC:TMOAF
|
NL |
|
Dynavax Technologies Corp
NASDAQ:DVAX
|
US |
|
S
|
Supalai PCL
SET:SPALI
|
TH |
Wall St Price Targets
DPHARMA Price Targets Summary
Duopharma Biotech Bhd
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.76 MYR with a low forecast of 1.64 MYR and a high forecast of 1.97 MYR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DPHARMA's stock price target?
Price Target
1.76
MYR
According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.76 MYR with a low forecast of 1.64 MYR and a high forecast of 1.97 MYR.
What is the Revenue forecast for Duopharma Biotech Bhd?
Projected CAGR
6%
Over the last 14 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 6%.
What is the Operating Income forecast for Duopharma Biotech Bhd?
Projected CAGR
5%
Over the last 14 years, the compound annual growth rate for Operating Income has been 10%. The projected CAGR for the next 3 years is 5%.
What is the Net Income forecast for Duopharma Biotech Bhd?
Projected CAGR
10%
Over the last 14 years, the compound annual growth rate for Net Income has been 9%. The projected CAGR for the next 3 years is 10%.
